Literature DB >> 1640920

National action plan to combat multidrug-resistant tuberculosis.

.   

Abstract

At no time in recent history has tuberculosis (TB) been as great a concern as it is today. TB cases are on the increase, and the most serious aspect of the problem is the recent occurrence of outbreaks of multidrug-resistant (MDR) TB, which pose an urgent public health problem and require rapid intervention. A Task Force composed of representatives of many federal agencies has developed a National Action Plan for addressing this problem. The Task Force identified a number of objectives to be met if MDR-TB is to be successfully combatted. These objectives fall under the categories of a) surveillance and epidemiology--determining the magnitude and nature of the problem; b) laboratory diagnosis--improving the rapidity, sensitivity, and reliability of diagnostic methods for MDR-TB; c) patient management--effectively managing patients who have MDR-TB and preventing patients with drug-susceptible TB from developing drug-resistant disease; d) screening and preventive therapy--identifying persons who are infected with or at risk of developing MDR-TB and preventing them from developing clinically active TB; e) infection control--minimizing the risk of transmission of MDR-TB to patients, workers, and others in institutional settings; f) outbreak control; g) program evaluation--ensuring that TB programs are effective in managing patients and preventing MDR-TB; h) information dissemination/training and education; and i) research to provide new, more effective tools with which to combat MDR-TB. The Action Plan lays out a series of activities to be undertaken at the national level. For each category, the Plan presents statements of problems to be overcome, followed by a summary of the objective to be achieved and steps to be carried out. For each implementation step, responsibility is assigned to the appropriate organization and start-up dates are listed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640920

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  8 in total

1.  Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  F Ardito; B Posteraro; M Sanguinetti; S Zanetti; G Fadda
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 2.  Epidemiology of Tuberculosis in the United States.

Authors:  Adam J Langer; Thomas R Navin; Carla A Winston; Philip LoBue
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 2.878

3.  Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.

Authors:  L Fox; M R Kramer; I Haim; R Priess; A Metvachuk; D Shitrit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-24       Impact factor: 3.267

Review 4.  Tuberculosis and HIV infection: a review.

Authors:  D Schürmann; S D Nightingale; F Bergmann; B Ruf
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 7.455

5.  Health-care workers' perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting.

Authors:  Jennifer R Zelnick; Andrew Gibbs; Marian Loveday; Nesri Padayatchi; Max R O'Donnell
Journal:  J Public Health Policy       Date:  2013-05-30       Impact factor: 2.222

Review 6.  Tuberculosis: a health education imperative returns.

Authors:  G L White; B H Henthorne; S E Barnes; J T Segarra
Journal:  J Community Health       Date:  1995-02

7.  Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally.

Authors:  Kenneth G Castro; Philip LoBue
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

8.  Effect of maternal immune status on responsiveness of bacillus calmette-gurin vaccination in mouse neonates.

Authors:  Jong Su Choi; Ryang Yeo Kim; Semi Rho; Fanny Ewann; Nathalie Mielcarek; Man Ki Song; Cecil Czerkinsky; Jae-Ouk Kim
Journal:  Osong Public Health Res Perspect       Date:  2012-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.